11 citations
,
September 2005 in “International Wound Journal” A woman developed severe skin damage after using a blood thinner called low-molecular-weight heparin.
July 2024 in “Reactions Weekly” Naproxen can cause serious lung issues, but high-dose aspirin might be safer.
21 citations
,
August 1960 in “British journal of dermatology/British journal of dermatology, Supplement” Endoxan often causes hair loss, which usually starts in the third week of treatment.
33 citations
,
May 2017 in “Journal of Clinical Oncology” ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.
322 citations
,
October 2006 in “British Journal of Clinical Pharmacology” Warfarin is effective but risky, requiring careful monitoring to prevent bleeding.
March 2012 in “Reactions Weekly” A man had a rare skin reaction from a hair loss medication, which improved after stopping the drug.
November 2009 in “Hair transplant forum international” Doctors should collaborate with the patient's primary care physician to decide if it's safe to stop taking Plavix before hair restoration surgery, considering the risk and benefit.
1 citations
,
January 2022 in “Journal of Cancer Therapy” Ocoxin improves quality of life for advanced ovarian cancer patients on chemotherapy.
2 citations
,
November 2025 in “Pharmacology Research & Perspectives” Avacopan may cause unexpected side effects, so early monitoring is important.
12 citations
,
March 2016 in “Life Sciences” The new chemotherapy combination of WP 631 and Epothilone B shows enhanced effectiveness against ovarian cancer but requires more research on its safety.
April 2016 in “Journal of The American Academy of Dermatology” Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.
December 2015 in “Vascular Pharmacology” Different cells affect hair follicle blood vessels, endothelial cells react differently to inflammation and oxidized fats, and prasugrel better protects heart vessels during a procedure than clopidogrel.
April 2026 in “Frontiers in Medicine” Enfortumab vedotin can cause skin issues, especially in older males, needing early monitoring.
May 2025 in “The Journal of Rheumatology” Early diagnosis and treatment are crucial for CAPS, and Eculizumab can be effective.
1 citations
,
November 2011 in “InTech eBooks” Citrate is a safer alternative to heparin for preventing blood clots in hemodialysis.
168 citations
,
December 1986 in “Cancer Chemotherapy and Pharmacology” Epirubicin is as effective as doxorubicin for cancer treatment with less heart damage, but doesn't work on doxorubicin-resistant cancers.
43 citations
,
August 2016 in “International Journal of Nanomedicine” Eupafolin nanoparticles help protect skin cells from damage caused by air pollution.
5 citations
,
January 2018 in “Indian Journal of Dermatology/Indian journal of dermatology” A woman got a skin rash from taking aceclofenac, which went away after she stopped the drug.
March 2026 in “Frontiers in Pharmacology” Exprecell™ is as effective as traditional methods but produces more f-PRF and is simpler to use.
8 citations
,
February 2024 in “Burns”
2 citations
,
August 2025 in “Scientific Reports” Pexidartinib often causes liver issues and fatigue, especially in women.
1 citations
,
October 2011 in “Hospital Pharmacy” September 2023 in “Journal of the American Academy of Dermatology” Ixekizumab is safe for long-term use with low rates of major heart-related events.
45 citations
,
October 2018 in “JCI Insight” Entospletinib effectively prevents eye and skin GVHD in mice.
1 citations
,
October 2025 in “Frontiers in Immunology” Avacopan is generally safe, with some minor side effects like nausea and fatigue.
8 citations
,
November 2012 in “Blood” Hair loss can be a side effect of certain blood thinners.
December 2015 in “Vascular Pharmacology” Prasugrel is better than clopidogrel at preventing heart damage and improving blood flow in small heart vessels during heart artery procedures.
October 2025 in “Actualización en Medicina de Familia” New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.
January 2004 in “Indian Journal of Nephrology”